Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

NEBU-ONE

Financiado

Cerrado

NEBU ONE A revolutionary method for anatomic pathology slides staining

Anatomic pathology laboratories (APL) across Europe have a responsibility to urgently modernize and sustain increasing efficiency, leverage automation, and foster patient safety. Misidentification errors in laboratories have the c... ver más

31/07/2016

Optana

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

OPTANA TECHNOLOGIES No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2016-07-31

PHC-12-2015-1: Clinical research for the validatio...

I+D

Cerrada hace 9 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

Optana

50.00K€ | Lider

Proyectos interesantes

UNLP10-3E-1066

Medical Technol...

Software

60K€ Cerrado

EUR 20080050 SISTEMA DE DIAGNOSTICO AUTOMATI...

Medical Technol...

Software

795K€ Cerrado

Prometeo

Medical Technol...

Data Science

71K€ Cerrado

PTQ-12-05255

Medical Technol...

Medical Devices

100K€ Cerrado

IntraMEMS

Medical Technol...

Data Science

150K€ Cerrado

EQC2019-006454-P

Medical Technol...

Data Science

197K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 5 meses Fecha Inicio: 2016-02-26
Fecha Fin: 2016-07-31

Líder del proyecto

OPTANA TECHNOLOGIES No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 71K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Anatomic pathology laboratories (APL) across Europe have a responsibility to urgently modernize and sustain increasing efficiency, leverage automation, and foster patient safety. Misidentification errors in laboratories have the capability to cause devastating events, both at medical and economic level. It is estimated that 30% of cytological cell samples are misinterpreted as negative for cancer. That represents 1.65 millions of samples per year. One of the most important problems for APL is the increase of the number of biological screening samples to be processed due to the lengthening of the lifetime and increased number of cancers. Only screening of cervical cancer, which represents today about 200 million tests worldwide and the market of about 1 milliard of euros, should double by 2020. Optana Technologies is developing a breakthrough medical device called NEBU-ONE, for highly improved and automated biological sample staining. NEBU-ONE contains a proprietary nebulization heads which deposits staining reagents in the form of aerosol (microdroplets) allowing them to penetrate much deeper and much faster into the tested samples (cells and tissues) compared to standard techniques. Often present cross-contamination between samples will be also decreased, as well as a consumption of expensive and pollutants reagents. All these will lead to increased quality of sample staining, improved accuracy of the analysis and interpretation and better diagnosis and patient care. It will allow Optana Technologies to become the reference method in the APLs and to grow rapidly in the European market. We plan to achieve the turnover of 4.3 M€ in 2020 and create 5 new highly qualified post. This feasibility study is essential to validate our innovative business model and NEBU-ONE before its transfer in routine laboratory practice and industrial production.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores